Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations highlighting the use of real-world data to identify resistance to early treatment in advanced breast cancer and the use of enhanced biomarker analysis to evaluate progression-free survival data in metastatic breast cancer therapy.

"We look forward to sharing an array of robust data at ASCO that demonstrate the utility of our blood tests to help healthcare professionals optimize care for patients at all stages of the disease?from detecting early-stage cancers to identifying the presence of residual disease and delivering insights that inform treatment to improve outcomes," said Helmy Eltoukhy, Guardant Health co-CEO. "We'll be presenting data from retrospective and real-world analyses that show how blood-based tests provide critical insights at every step of a patient's treatment journey, and analytics that contribute to the broader scientific community's understanding of some of the most challenging cancers."

Full List of Guardant Health Presentations

Guardant360

Guardant Reveal

Guardant360 Response

GuardantINFORM

GuardantOMNI

Shield LDT ? CRC Screening

Next generation Shield ? Multi-Cancer Screening

The full abstracts will be available on the official ASCO website on May 26, 2022.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNexttm, Guardant360 Responsetm, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Revealtm for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shieldtm test, aims to address the needs of individuals eligible for cancer screening.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.


These press releases may also interest you

at 20:05
Nutricosmetics Market Facts at a Glance- Companies: 10+ ? Including ActivInside, Borba LLC, Functionalab, Herbalife Nutrition Ltd.,...

at 20:00
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of...

at 18:00
ATC Healthcare Services, LLC ("ATC" the "Company") is making individuals aware of an incident that may affect the privacy of certain information. Although ATC is unaware of any actual or attempted misuse of such information, the Company is providing...

at 17:39
Reckitt is proud to provide the largest delivery of infant formula to the United States on three UPS flights from our world-class facility in Tuas, Singapore, facilitated by the White House's Operation Fly Formula initiative. With Reckitt's...

at 17:04
*  Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine) are the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators as...

at 17:00
Lighthouse Health & Wellness is excited to announce that it has acquired Academy Hour, in a move that will further support the health and wellness of first responders nationwide. COMBINING FORCES FOR PUBLIC SAFETY'S GOOD The merging of Academy Hour...



News published on 23 may 2022 at 08:15 and distributed by: